Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism

被引:27
|
作者
Castelli, Germana [1 ]
Pelosi, Elvira [1 ]
Testa, Ugo [1 ]
机构
[1] Ist Super Sanita, Dept Oncol, Viale Regina Elena 299, I-00161 Rome, Italy
关键词
apoptosis; acute myeloid leukemia; leukemia; TRAIL; BCL-2; MCL-1; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; FATTY-ACID OXIDATION; TRAIL-INDUCED APOPTOSIS; INTEGRATED STRESS-RESPONSE; BCL-2 FAMILY PROTEINS; SENSITIZES AML CELLS; MULTICENTER PHASE-II; CLONAL HEMATOPOIESIS; STEM-CELLS;
D O I
10.3390/cancers11020260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute Myelogenous Leukemia (AML) is a malignant disease of the hematopoietic cells, characterized by impaired differentiation and uncontrolled clonal expansion of myeloid progenitors/precursors, resulting in bone marrow failure and impaired normal hematopoiesis. AML comprises a heterogeneous group of malignancies, characterized by a combination of different somatic genetic abnormalities, some of which act as events driving leukemic development. Studies carried out in the last years have shown that AML cells invariably have abnormalities in one or more apoptotic pathways and have identified some components of the apoptotic pathway that can be targeted by specific drugs. Clinical results deriving from studies using B-cell lymphoma 2 (BCL-2) inhibitors in combination with standard AML agents, such as azacytidine, decitabine, low-dose cytarabine, provided promising results and strongly support the use of these agents in the treatment of AML patients, particularly of elderly patients. TNF-related apoptosis-inducing ligand (TRAIL) and its receptors are frequently deregulated in AML patients and their targeting may represent a promising strategy for development of new treatments. Altered mitochondrial metabolism is a common feature of AML cells, as supported through the discovery of mutations in the isocitrate dehydrogenase gene and in mitochondrial electron transport chain and of numerous abnormalities of oxidative metabolism existing in AML subgroups. Overall, these observations strongly support the view that the targeting of mitochondrial apoptotic or metabolic machinery is an appealing new therapeutic perspective in AML.
引用
收藏
页数:77
相关论文
共 50 条
  • [31] Mitochondria as emerging targets for therapies against Tcell acute lymphoblastic leukemia
    Olivas-Aguirre, Miguel
    Pottosin, Igor
    Dobrovinskaya, Oxana
    JOURNAL OF LEUKOCYTE BIOLOGY, 2019, 105 (05) : 935 - 946
  • [32] New directions for emerging therapies in acute myeloid leukemia: the next chapter
    Daver, Naval
    Wei, Andrew H.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Vyas, Paresh
    DiNardo, Courtney D.
    BLOOD CANCER JOURNAL, 2020, 10 (10)
  • [33] Emerging antibody-based therapies for the treatment of acute myeloid leukemia
    Angenendt, Linus
    Mikesch, Jan-Henrik
    Schliemann, Christoph
    CANCER TREATMENT REVIEWS, 2022, 108
  • [34] New directions for emerging therapies in acute myeloid leukemia: the next chapter
    Naval Daver
    Andrew H. Wei
    Daniel A. Pollyea
    Amir T. Fathi
    Paresh Vyas
    Courtney D. DiNardo
    Blood Cancer Journal, 10
  • [35] New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
    Chen, Jing
    Glasser, Chana L.
    CHILDREN-BASEL, 2020, 7 (02):
  • [36] Targeting the mitochondrial quality control machinery in acute myeloid leukemia
    Jeyaraju, Danny V.
    Voisin, Veronique
    Ramakrishnan, Ashwin
    Hurren, Rose
    Maclean, Neil
    Gronda, Marcela
    Minden, Mark
    Bader, Gary
    Schimmer, Aaron D.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [37] Targeting prohibitins induces apoptosis in acute myeloid leukemia cells
    Pomares, Helena
    Palmeri, Claudia M.
    Iglesias-Serret, Daniel
    Moncunill-Massaguer, Cristina
    Saura-Esteller, Jose
    Nunez-Vazquez, Sonia
    Gamundi, Enric
    Arnan, Montserrat
    Preciado, Sara
    Albericio, Fernando
    Lavilla, Rodolfo
    Pons, Gabriel
    Gonzalez-Barca, Eva M.
    Cosialls, Ana M.
    Gil, Joan
    ONCOTARGET, 2016, 7 (40) : 64987 - 65000
  • [38] Dual targeting of glutamine and serine metabolism in acute myeloid leukemia
    Hameed, Kanwal M.
    Bollino, Dominique R.
    Shetty, Amol C.
    Carter-Cooper, Brandon
    Lapidus, Rena G.
    Emadi, Ashkan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia
    Pardee, Timothy
    DeFord-Watts, Laura M.
    Peronto, Erica
    Levitan, Denise A.
    Hurd, David Duane
    Kridel, Steven
    BLOOD, 2011, 118 (21) : 1546 - 1546
  • [40] Targeting polyamines metabolism in acute myeloid leukemia stem cells
    Rondeau, Vincent
    Culp-Hill, Rachel
    O'Brien, Cristiana
    Berman, Jacob
    Reisz, Julie A.
    Yendi, Duhan
    Ling, Tianyi
    Janangiri, Soheil
    Tikhonova, Anastasia
    D'Alessandro, Angelo
    Jones, Courtney
    CANCER RESEARCH, 2023, 83 (07)